Blue Jet Healthcare Ltd
Blue Jet Healthcare Q3 FY26: Capex ₹410 Cr
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Get Blue Jet Healthcare Ltd's next results in your feed
Guidance rank: #23 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The gadolinium-based NCE product is expected to reach a steady state with stable and sustainable yearly sales; modest growth possible in FY27 (Page 17). FY27 outlook is cautiously positive with expected commercial launch and ramp-up in key molecules starting Q1 FY27 (Page 13).
From Blue Jet Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The gadolinium-based NCE product is expected to reach a steady state with stable and sustainable yearly sales; modest growth possible in FY27 (Page 17).
- Contrast media segment’s new launches and portfolio expansion aim to increase wallet share with large innovators, suggesting growth potential (Page 15).
- FY27 expected to see commercial launch and ramp-up of new cardiovascular and NCE intermediate molecules contributing positively to revenue (Page 13).
- Incremental pipeline includes new contrast media and API/PI products, indicating diversification and potential growth beyond current concentrations (Page 13).
2 more points from Blue Jet Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vizag Greenfield Project: Rs.1,000 crores approved CAPEX over the next 3-4 years to set up dedicated API and intermediates capacity aligned with customer demand; groundbreaking scheduled for February 2026; expected to strengthen global positioning.
- Unit 3 Expansion (Mahad): Nearing completion of core block for backward integration into contrast media intermediates; designed with automation and safety features; ready for qualification in Q1 FY27 to support growth and de-bottleneck supply chain.
- Hyderabad R&D Expansion: New R&D center lease secured; development to start from Q3 FY27 focusing on emerging technologies like intermediates for GLP-1s, peptide chemistry, and bio-catalysis to support growing CDMO pipeline.
2 more points from Blue Jet Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- For the API, PI molecule, Blue Jet has binding forecasts and confirmed purchase orders for FY27, indicating a reasonably stable and sustainable order book.
- The orders are partly subject to ongoing renegotiations, but historical momentum and multi-year supply agreements lend stability.
- The company expects some lumpiness in pharma intermediates orders due to CDMO nature but aims for incremental year-on-year growth over the next five years.
2 more points from Blue Jet Healthcare Ltd's call on order book
Create a free account to keep reading this call
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Blue Jet Healthcare Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 192 | 318 | -39.6% | 165 | +16.4% |
| Operating profit (EBITDA) | 47 | 124 | -62.1% | 55 | -14.5% |
| Operating margin | 24% | 39% | -15 pp | 33% | -9 pp |
| Profit before tax | 54 | 132 | -59.1% | 69 | -21.7% |
| Net profit (PAT) | 40 | 99 | -59.6% | 52 | -23.1% |
| EPS (₹) | 2.32 | 5.71 | -59.4% | 3.01 | -22.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q3 FY26 results?
The gadolinium-based NCE product is expected to reach a steady state with stable and sustainable yearly sales; modest growth possible in FY27 (Page 17). FY27 outlook is cautiously positive with expected commercial launch and ramp-up in key molecules starting Q1 FY27 (Page 13).
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Vizag Greenfield Project: Rs.1,000 crores approved CAPEX over the next 3-4 years to set up dedicated API and intermediates capacity aligned with customer demand; groundbreaking scheduled for February 2026; expected to strengthen global positioning.
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.